ACT Stock Recent News

-       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy -       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy -       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK , May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commerci

Stocks like ATKR, ACT, POOL and AWK recently announced dividend hikes.

Enact Holdings, Inc. (NASDAQ:ACT ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Daniel Kohl - Vice President of Investor Relations Rohit Gupta - President and Chief Executive Officer Dean Mitchell - Chief Financial Officer Conference Call Participants Mihir Bhatia - Bank of America Merrill Lynch Douglas Harter - UBS Richard Shane - JPMorgan Chase & Co. Bose George - Keefe, Bruyette, & Woods, Inc. Operator Hello, and welcome to Enact's First Quarter Earnings Call. Please be advised that today's conference is being recorded.

GAAP Net Income of $166 million , or $1.08 per diluted share Adjusted Operating Income of $169 million , or $1.10 per diluted share Return on Equity of 13.1% and Adjusted Operating Return on Equity of 13.4% Primary Insurance in-force of $268 billion , a 2% increase from first quarter 2024 PMIERs Sufficiency of 165% or approximately $2.0 billion Book Value Per Share of $33.96 and Book Value Per Share excluding AOCI of $34.97

RALEIGH, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) announced that its Board of Directors declared a quarterly dividend of $0.21 per common share, an increase of 14% from the prior quarter's dividend. This dividend will be payable on June 11, 2025, to shareholders of record on May 19, 2025.

MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, showcases its latest zero- and ultra-low emission commercial vehicle platforms at the upcoming 2025 Advanced Clean Transportation (ACT) Expo, North America's largest advanced transportation technology event. The company presents both its groundbreaking electric step van and propane-powered stripped chassis at the industry event from April 28-30, 2025, at the Anaheim Conventio.

RALEIGH, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its first quarter earnings release after the market closes on April 30, 2025. Enact will host a conference call to review first quarter 2025 financial results on May 1, 2025 at 8:00 a.m. (ET).

NEW YORK , April 9, 2025 /PRNewswire/ -- Enact Holdings Inc. (NASD: ACT) will replace SolarWinds Corp. (NYSE: SWI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, April 16. Turn/River Capital is acquiring SolarWinds in a deal expected to close soon, pending final closing conditions.

Arcady Sosinov, appointed Tritium CEO in December 2024, announces a next-generation ultra-scaling EV charging solution that will be revealed April 28, 2025 at ACT Expo in Anaheim, Calif. Arcady Sosinov, appointed Tritium CEO in December 2024, announces a next-generation ultra-scaling EV charging solution that will be revealed April 28, 2025 at ACT Expo in Anaheim, Calif.

RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced the release of its 2024 Sustainability Report covering the calendar year 2024.